Background
Prevalence and factors associated with obstructive and restrictive lung function in people with chronic kidney disease (CKD) is unknown.
Study Design
Cross-sectional and longitudinal analyses
Setting & Participants
Participants aged 40–79 years from the NHANES (National Health and Nutrition Examination Survey) 2007–2012 who underwent spirometry testing.
Predictor
CKD (eGFR >15-<60 ml/min/1.73 m2 or urinary albumin-creatinine ratio ≥30 mg/g)
Outcomes
Restrictive lung function (defined as FEV1/FVC ≥0.70 and baseline FVC <80% predicted), obstructive lung function (defined as FEV1/FVC <0.70 based on post-bronchodilator spirometric results), and mortality data (available for 2007–2008 and 2009–2010 survey periods).
Results
7,610 participants (CKD=1338; Non-CKD=6272) were included. The prevalences of obstructive lung function adjusted to the mean age of 55 years and 50% male in the CKD and non-CKD groups were 15.6% and 13.3%, respectively (p=0.2). Similarly, adjusted prevalences of restrictive lung function in the CKD and non-CKD groups were 9.8% and 6.7%, respectively (p=0.01). Presence of albumin-creatinine ratio > 30 mg/g was associated with obstructive (OR, 1.42; 95% CI, 1.07–1.88) and restrictive lung function (OR, 1.43; 95% CI, 1.01–2.03) in the entire study cohort. eGFR < 60 mL/min/1.73m2 was associated with higher odds of obstructive lung function. In a multivariable Cox model, age (HR, 1.07; 95% CI, 1.04–1.11) and presence of obstructive lung function (HR, 2.68; 95% CI, 1.80–3.97) but not CKD measures were associated with death.
Limitations
Small proportion of participants with advanced kidney disease
Conclusions
In a representative sample of US adults, impaired lung function is common in those with and without CKD. Albuminuria was independently associated with both obstructive and restrictive lung function, and eGFR < 60 mL/min/1.73m2 was associated with higher odds of obstructive lung function. Older age and obstructive lung function were associated with higher likelihood of death. Further studies examining the burden of lung disease in advanced CKD are needed.